Primary mucosal and acral melanomas exhibit a lower frequency of activating BRAF mutations, with mutations in KIT and NRAS predominating.16 Identification of specific KIT gene mutations is essential to determine the sensitivity to KIT-inhibitor therapy (imatinib or nilotinib). Here, NRAS is linked to acral lentiginous melanoma.